一项新的研究结果更新了对脑血管疾病的认识，该研究由日本大阪的关西医科大学进行。研究聚焦于骨质疏松症治疗药物 Romosozumab (Rmab) 的心血管安全性，并将其与其他抗骨质疏松药物 (AOMs) 进行了比较。
研究人员利用日本的国家健康保险索赔数据库，评估了 Romosozumab 与其他抗骨质疏松药物相比，在患者中发生心血管疾病（CVD）的风险。研究结果显示，与甲状旁腺激素（PTH）相比，Romosozumab 在男性患者中的调整后风险比（HRs）显示出较低的心血管事件发生率。具体而言，Romosozumab 在急性心肌梗死方面的 HRs 为 0.49，在缺血性心脏病方面的 HRs 为 0.59，在脑血管疾病方面的 HRs 为 0.70。
这项名为“Romosozumab 与其他抗骨质疏松药物在骨质疏松症患者中的心血管安全性：一项日本全国健康保险索赔数据库研究”的详细研究，旨在深入了解 Romosozumab 在治疗骨质疏松症的同时，对心血管系统的影响。
问鼎APP: Get the Latest Hot Games
- Author: 问鼎 Editor
- Published on: 2026-07-17
- Category: Platform Dynamics
Download the 问鼎APP and start your new chapter in digital entertainment now. We are committed to providing the most cutting-edge platform introductions, version update news, and popular event information. 问鼎APP is your digital companion for discovering fun and sparking creativity. Download now and explore endless possibilities.
Download the 问鼎娱乐官方网站 APP to learn about platform introductions, version updates, popular events, and rich game information. Continuously improve user experience, bringing more convenient and interesting digital entertainment information services to users.
问鼎APP: Real-time Push for Updates and Events
问鼎APP continuously optimizes user experience with a simple and intuitive interface and smooth operation. Whether you are looking for the latest game guides or exclusive event information, you can easily get it. We provide 7x24 online customer service to offer professional support at any time, ensuring every interaction is incredibly smooth.